SCHEDULE: Vanguard Group Reports Zero Xeris Biopharma Holdings Stake

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Xeris Biopharma Holdings Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Xeris Biopharma Holdings Inc.
• The filing reports 0 shares beneficially owned, representing 0% of the class of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from the parent entity.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Xeris Biopharma, as it primarily reflects an internal reporting change by The Vanguard Group rather than a change in investment position or company fundamentals.

Future Outlook

No forward-looking statements or guidance regarding Xeris Biopharma Holdings Inc. are provided in this filing.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings primarily concern institutional ownership disclosures. This specific filing reflects an internal organizational change at The Vanguard Group, rather than a change in investment thesis regarding Xeris Biopharma Holdings Inc. The disaggregation of reporting by subsidiaries is a common practice for large asset managers to comply with SEC regulations.

Comparison to Industry Standards

• This filing is a standard regulatory update for a large institutional investor. It does not provide performance metrics for Xeris Biopharma to compare against industry standards or competitors.

Stakeholder Impact

• Shareholders of Xeris Biopharma Holdings Inc. should be aware that The Vanguard Group, Inc. (the parent entity) no longer directly reports beneficial ownership, but its subsidiaries will now report separately. This is a change in reporting structure, not necessarily a divestment by the broader Vanguard organization.

Key Dates

Keywords

Xeris Biopharma Holdings Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Realignment